Gyre Therapeutics (GYRE) Cash from Financing Activities (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Cash from Financing Activities of $21000.0 for Q1 2026, down 98.44% year-over-year from $1.3 million in Q1 2025, and down 93.4% quarter-over-quarter from $318000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Cash from Financing Activities for 17 consecutive years, with $21000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 98.44% year-over-year to $21000.0; the TTM figure through Mar 2026 stood at $23.1 million (up 726.94% YoY), while the FY2025 annual figure was $24.4 million, up 1059.75% from the prior year.
- Cash from Financing Activities fell to $21000.0 in Q1 2026 per GYRE's latest filing, from $318000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $22.4 million in Q2 2025 and bottomed at -$45.0 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged -$1.1 million across 5 years, with a median of $318000.0 in 2025.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 48612.5% — and 2025, when it jumped 14227.56%.
- Gyre Therapeutics' Cash from Financing Activities stood at -$45.0 million in 2022, then soared by 133.85% to $15.2 million in 2023, then slumped by 93.67% to $964000.0 in 2024, then slumped by 67.01% to $318000.0 in 2025, then sank by 93.4% to $21000.0 in 2026.
- Business Quant data shows GYRE's Cash from Financing Activities at $21000.0 in Q1 2026, $318000.0 in Q4 2025, and $365000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8,000.00 |
| Jun 30, 2026 | -8,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Sep 30, 2025 | 365,000.00 |
| Sep 30, 2025 | 365,000.00 |
| Jun 30, 2025 | 22.35 Mn |
| Jun 30, 2025 | 22.35 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 964,000.00 |
| Dec 31, 2024 | 964,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 658,000.00 |
| Mar 31, 2024 | 658,000.00 |